Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes

“…Compared to healthy bone marrows, MDS patients had less diverse TCR repertoires but higher degree of clonality, suggesting T cell expansion in response to MDS specific antigens. However, unlike previous studies (20,29,30), we did not identify significant skewness in CDR3 length of TCRs from MDS patients compared to healthy donors or following HMA treatment. Of note, healthy bone marrow donors were not agematched to MDS patients and could have impacted the comparison between healthy and MDS bone marrows.…”

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes

“…Compared to healthy bone marrows, MDS patients had less diverse TCR repertoires but higher degree of clonality, suggesting T cell expansion in response to MDS specific antigens. However, unlike previous studies (20,29,30), we did not identify significant skewness in CDR3 length of TCRs from MDS patients compared to healthy donors or following HMA treatment. Of note, healthy bone marrow donors were not agematched to MDS patients and could have impacted the comparison between healthy and MDS bone marrows.…”

Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine

“…From a strictly morphological point of view, azacitidine treatment had no significant impact on bone marrow cellularity or dysplastic features of the three hemopoietic lineages. On the other hand, we observed a slight post-treatment increase in bone marrow lymphoid infiltrate, ranging from a pre-treatment median value of 7.63% to a post-treatment median value of 8.29%, similarly to what was previously reported by cytofluorimetry studies [ 20 , 21 , 22 ]. Inflammatory infiltrates showed an interstitial distribution with scattered microaggregates and they were mainly composed of T-cells, variably admixed with a minority of B-cells.…”

Evidence of a skewed T‐cell repertoire in patients with light chain amyloidosis

“…The presence of a dominant peak with a relative intensity greater than 50% of the total peak area is usually used to specifically identify oligoclonal subfamilies (panel E) in the degree of CDR3 skewing in their T-cell repertoire involving both CD4+ and CD8+ cells. Altered TCR repertoire patterns have already been shown to characterize different malignancies [2][3][4][5] and to be potentially reversible after anti-neoplastic treatment [14]. In more details, a similar pattern has been recently demonstrated in patients with non Hodgkin lymphomas [3], while in different disorders, such as myelodysplastic syndromes, the increased degree of skewing was confined to the CD8+ subset [4].…”

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes

“…Compared to healthy bone marrows, MDS patients had less diverse TCR repertoires but higher degree of clonality, suggesting T cell expansion in response to MDS specific antigens. However, unlike previous studies (20,29,30), we did not identify significant skewness in CDR3 length of TCRs from MDS patients compared to healthy donors or following HMA treatment. Of note, healthy bone marrow donors were not agematched to MDS patients and could have impacted the comparison between healthy and MDS bone marrows.…”

Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine

“…From a strictly morphological point of view, azacitidine treatment had no significant impact on bone marrow cellularity or dysplastic features of the three hemopoietic lineages. On the other hand, we observed a slight post-treatment increase in bone marrow lymphoid infiltrate, ranging from a pre-treatment median value of 7.63% to a post-treatment median value of 8.29%, similarly to what was previously reported by cytofluorimetry studies [ 20 , 21 , 22 ]. Inflammatory infiltrates showed an interstitial distribution with scattered microaggregates and they were mainly composed of T-cells, variably admixed with a minority of B-cells.…”

Evidence of a skewed T‐cell repertoire in patients with light chain amyloidosis

“…The presence of a dominant peak with a relative intensity greater than 50% of the total peak area is usually used to specifically identify oligoclonal subfamilies (panel E) in the degree of CDR3 skewing in their T-cell repertoire involving both CD4+ and CD8+ cells. Altered TCR repertoire patterns have already been shown to characterize different malignancies [2][3][4][5] and to be potentially reversible after anti-neoplastic treatment [14]. In more details, a similar pattern has been recently demonstrated in patients with non Hodgkin lymphomas [3], while in different disorders, such as myelodysplastic syndromes, the increased degree of skewing was confined to the CD8+ subset [4].…”

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes

“…Compared to healthy bone marrows, MDS patients had less diverse TCR repertoires but higher degree of clonality, suggesting T cell expansion in response to MDS specific antigens. However, unlike previous studies (20,29,30), we did not identify significant skewness in CDR3 length of TCRs from MDS patients compared to healthy donors or following HMA treatment. Of note, healthy bone marrow donors were not agematched to MDS patients and could have impacted the comparison between healthy and MDS bone marrows.…”

Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine

“…From a strictly morphological point of view, azacitidine treatment had no significant impact on bone marrow cellularity or dysplastic features of the three hemopoietic lineages. On the other hand, we observed a slight post-treatment increase in bone marrow lymphoid infiltrate, ranging from a pre-treatment median value of 7.63% to a post-treatment median value of 8.29%, similarly to what was previously reported by cytofluorimetry studies [ 20 , 21 , 22 ]. Inflammatory infiltrates showed an interstitial distribution with scattered microaggregates and they were mainly composed of T-cells, variably admixed with a minority of B-cells.…”

Evidence of a skewed T‐cell repertoire in patients with light chain amyloidosis

“…The presence of a dominant peak with a relative intensity greater than 50% of the total peak area is usually used to specifically identify oligoclonal subfamilies (panel E) in the degree of CDR3 skewing in their T-cell repertoire involving both CD4+ and CD8+ cells. Altered TCR repertoire patterns have already been shown to characterize different malignancies [2][3][4][5] and to be potentially reversible after anti-neoplastic treatment [14]. In more details, a similar pattern has been recently demonstrated in patients with non Hodgkin lymphomas [3], while in different disorders, such as myelodysplastic syndromes, the increased degree of skewing was confined to the CD8+ subset [4].…”